Scientific deep-dive
Tirzepatide Long-Term Side Effects: Where the Evidence Stops
The longest published randomized tirzepatide treatment in obesity is 176 weeks, and the cardiovascular trial ran a median of 46.9 months. This separates what the approved label warns about from what a trial counted, and says where the record ends.
Part of Safety and side effects, separated from the headlines
The longest published randomized experience with tirzepatide in obesity is 176 weeks (a little under three and a half years), and that figure comes from one subgroup of one trial.[4] In type 2 diabetes there is a cardiovascular outcome trial with a median of 46.9 months of treatment.[7] Past those horizons there are no data, only opinions. So the useful version of “long-term side effects” is two separate questions: what the approved label warns about, and how much of that warning is backed by a counted number.
How far the record reaches
Tirzepatide is not an old drug. FDA cleared the molecule first for type 2 diabetes, under the name Mounjaro, on May 13, 2022, and then for weight reduction, as Zepbound, on November 8, 2023.[9][10] Everything anyone knows about taking it for years comes from a small number of trials that were designed to end. The same is true across the class, as our list of the longest GLP-1 studies shows. This page is about how far that evidence reaches; for how long an individual symptom tends to last, see how long GLP-1 side effects last.
| Trial | Population | How long | What it was built to answer |
|---|---|---|---|
| SURMOUNT-1, primary report | 2,539 adults with obesity or overweight, no diabetes | 72 weeks, including a 20-week escalation period | Weight change and tolerability.[3] |
| SURMOUNT-1, 3-year report | The 1,032 of those participants who also had prediabetes | 176 weeks on assigned treatment, then 17 weeks off it | Whether progression to type 2 diabetes was delayed, plus 3-year safety.[4] |
| SURMOUNT-4 | 670 adults randomized after an open-label run-in | 36-week lead-in, then 52 weeks blinded — 88 weeks total | What happens to weight when the drug is withdrawn.[5] |
| SURPASS-CVOT | 13,299 adults who had both type 2 diabetes and established atherosclerotic disease | Median treatment duration 46.9 months | Whether tirzepatide was noninferior to dulaglutide on cardiovascular events.[6][7] |
The three-year report is the one people mean when they say the drug has long-term data. It found substantial weight reduction sustained to week 176 and markedly fewer diabetes diagnoses than placebo, 1.3 percent against 13.3 percent, and its safety conclusion was a single sentence: no new safety signals were identified.[4] Read that sentence precisely. It says nothing new appeared over three years, not that nothing new exists at five.
A trial built to answer the outcome question in obesity is running. SURMOUNT-MMO enrolled 15,374 participants, is listed as active and no longer recruiting, and has a primary completion date of October 2027.[11] Until it reports, the morbidity and mortality question for people taking tirzepatide without diabetes has no trial answer at all. What the death data do show, and what they do not, is in tirzepatide and longevity.
A warning is not a rate
This is the distinction that decides how worried to be, and almost nothing written about GLP-1 drugs preserves it. A warning in an approved label is a disclosure FDA required, based on a plausible association, an animal finding, or reports gathered after approval. A rate is the result of counting events among people who were randomized. The two look identical on a page of bullet points and mean very different things.
The table below reads the Zepbound label, because that is the presentation approved for weight reduction. Mounjaro, the same molecule approved for type 2 diabetes, carries the same set of warnings, with the retinopathy one written for patients who already have a history of diabetic retinopathy. Since August 2026 it also carries a cardiovascular indication that Zepbound does not.[2] If you are taking tirzepatide for diabetes, that is the label your prescription is written against.
| Labeled concern | What the label rests it on | Is there a rate? |
|---|---|---|
| Thyroid C-cell tumors, including medullary thyroid carcinoma | A 2-year rat study. The label states plainly that human relevance has not been determined.[1] | No human rate. The finding is in rats. |
| Acute pancreatitis | Cases seen in people on this drug and on GLP-1 receptor agonists generally. The warning section attaches no number to them.[1] | Yes, elsewhere in the label, and it matches placebo. Adjudicated acute pancreatitis was 0.2% on tirzepatide and 0.2% on placebo in the pooled weight trials.[1] |
| Acute gallbladder disease | An increased occurrence with tirzepatide and with GLP-1 receptor agonists, associated with weight reduction.[1] | Yes, and it is small but real. Cholecystitis 0.7% against 0.2%; cholelithiasis 1.1% against 1%; cholecystectomy 0.2% against none.[1] |
| Acute kidney injury from volume depletion | Postmarketing reports, some requiring hemodialysis, mostly in people who had lost fluid through nausea, vomiting or diarrhea.[1] | No trial rate. Postmarketing reports have no denominator. |
| Diabetic retinopathy complications | Temporary worsening has been reported when glucose control improves quickly. An August 2026 revision dropped the earlier list of retinopathy populations never studied.[1] | No rate in this label. It is a monitoring instruction for people with a retinopathy history. |
| Severe gastrointestinal reactions | Reported more often on drug than placebo in the pooled weight trials; not recommended in severe gastroparesis.[1] | Yes. 1.7%, 2.5% and 3.1% by dose, against 1% on placebo.[1] |
Read the pancreatitis row twice. Pancreatitis is the risk people fear most on these drugs, it carries a full warning section, and in the pooled weight-reduction trials the adjudicated rate on tirzepatide was the same as the rate on placebo. That does not make the warning wrong or removable. The warning is doing what a warning does, telling a clinician what to watch for; it is not evidence that the drug caused pancreatitis at a measurable rate in those trials.
The boxed warning, read carefully
The strongest warning on the label is the one at the top, and it is entirely an animal finding.
In a two-year rat study, thyroid C-cell tumors rose with the size of the dose and with how long the animals were exposed, at exposures the label calls clinically relevant.[1] Whether the same thing happens in people has, in the label's own phrasing, not been determined.[1] Nothing stronger than that is claimed, and nothing weaker is permitted either: the warning sits in a black box at the top of the document.
Two things follow from it, and only two. The first is a hard contraindication for anyone carrying type 2 multiple endocrine neoplasia syndrome and for anyone whose own medical record or family record includes medullary thyroid carcinoma.[1] That is absolute, and it is a question to answer honestly with a prescriber before starting rather than a risk to weigh. The second is a short list of symptoms to watch for: a mass in the neck, difficulty swallowing, shortness of breath, persistent hoarseness.[1]
What does not follow is a screening plan. The label describes routine calcitonin testing and thyroid ultrasound as being of uncertain value for catching MTC early, and as carrying their own risk of setting off procedures nobody needed.[1] Anyone selling you a thyroid panel as GLP-1 safety monitoring is going past the label.
What the cardiovascular trial does and does not cover
SURPASS-CVOT is the longest controlled safety experience with tirzepatide that exists. It randomized 13,299 adults who had type 2 diabetes alongside established atherosclerotic disease, assigning them either tirzepatide or dulaglutide (whose cardiovascular benefit was already established), and ran to a median treatment duration of 46.9 months.[6][7] Heart attack, stroke or cardiovascular death, the primary composite, struck 12.2 percent of the tirzepatide group and 13.1 percent of the dulaglutide group: noninferior, and not statistically superior.[6]
For a long-term side effect question, the value of that trial is the four years of blinded follow-up rather than the efficacy verdict. Adverse events were broadly similar between the two groups, with more gastrointestinal events on tirzepatide (42.5 percent against 35.9 percent in the post hoc analysis of the same population).[7] There is a ceiling on what it transfers to, though. Everyone in it had diabetes and established heart disease, and they were compared against another incretin drug rather than against nothing. Zepbound's approved indications are weight reduction and obstructive sleep apnea; the label carries no cardiovascular risk-reduction claim.[1]
Mounjaro's label now does. In August 2026 FDA gave it a second indication: cutting major cardiovascular events, meaning cardiovascular death, heart attack or stroke, among high-risk adults who have type 2 diabetes. The clinical studies section behind it is SURPASS-CVOT. The same section states that superiority to dulaglutide was not established.[2] The indication rests on matching a comparator that already held a cardiovascular claim, not on beating placebo. It also stays inside the trial's population: diabetes and high cardiovascular risk.
Muscle: the part that is measured, and the part that is not
Lean-mass loss is the long-term worry that has traveled furthest ahead of its evidence, so start with what was measured. A substudy of SURMOUNT-1 scanned 160 of the 2,539 participants by DXA at baseline and week 72. On tirzepatide, body weight fell 21.3 percent, fat mass 33.9 percent and lean mass 10.9 percent; on placebo the corresponding figures were 5.3, 8.2 and 2.6 percent.[8]
The ratio matters more than any single number. About 75 percent of what came off was fat and about 25 percent was lean tissue, and that split was about the same in the placebo group.[8] So the composition of the loss looked like weight loss, not like a specific effect of the drug on muscle. Losing a quarter of your lost weight as lean mass still matters, particularly if you are older, and it is a reason to raise resistance training and protein intake with a clinician. It is not evidence that tirzepatide dissolves muscle.
Stopping: the best-documented long-term effect there is
SURMOUNT-4 was built to answer exactly this. Participants took tirzepatide open-label for 36 weeks, at which point 670 of them were randomly assigned to stay on the drug or move to placebo for 52 more weeks. Between week 36 and week 88, weight changed by -5.5 percent in the group that continued and by +14.0 percent in the group that stopped.[5] Of those who continued, 89.5 percent still held at least 80 percent of their run-in weight loss at week 88, against 16.6 percent of those who stopped.[5] What stopping looks like in practice, including side effects and the half-life, is in stopping tirzepatide: weight regain and side effects.
The three-year trial adds a second angle. After 176 weeks of treatment and then 17 weeks with no drug at all, 2.4 percent of the tirzepatide participants had type 2 diabetes against 13.7 percent of the placebo participants. Some of the metabolic benefit survived the washout, even as weight began to come back.[4]
The practical reading is unglamorous: this behaves like ongoing therapy for a chronic condition, not like a course of something. That has consequences for supply, for cost, and for what happens when a program ends for reasons unconnected to anything you did. We walk through that situation in what to do when a compounded GLP-1 program ends. If you are thinking of stopping because of cost, tell your prescriber first, and compare the dated figures on our price tracker rather than a seller's headline.
If it is ongoing therapy, how a program bills over years matters as much as the first month. TMates and Collective charge the same at every dose of compounded tirzepatide, though Collective adds a required annual membership on top. Queen RX sells one-time three-month packs with no subscription, and AVARA Rx leaves each monthly refill for you to pay rather than billing it automatically.
Watch for the opposite model early, since most people climb the dose ladder over the first months. Coby Health prices compounded tirzepatide by dose, so the monthly charge goes up with each step from the 2.5 mg start. bmiMD takes the flat approach instead, charging $179 for a one-month plan of compounded tirzepatide at every dose.
Continuity of care counts for the same reason. YOURx Health runs care through MD Integrations with a physician video visit, and MediRX has OpenLoop Health’s clinicians prescribe. Blue Sky MD sells the medication only inside a full program with one-on-one coaching, and Harbor adds a registered dietitian after the medication phase ends, the stage the stopping trial above describes.
Where the record simply stops
- Beyond about three and a half years in obesity. 176 weeks is the end of the published randomized road, and that report covers the prediabetes subgroup.[4]
- Cancer risk in humans. The boxed warning is a rat study. A three-and-a-half-year trial is not long enough to settle a question about tumors that take decades to appear, and no trial of this length could be.[1][4]
- Outcomes in people without diabetes. The cardiovascular evidence comes from a diabetes population with established heart disease. SURMOUNT-MMO does not complete until October 2027.[6][11]
- Function, as opposed to tissue mass. The body-composition data describe what was lost, not what changed about strength.[8]
- Anything about compounded tirzepatide over years. There is no trial of any compounded formulation, at any duration, which is a separate problem we take apart in compounded tirzepatide side effects.
This is what a young drug's evidence base looks like, and a seller who answers a long-term safety question with more confidence than the trials support is telling you something about the seller. Which pharmacy stands behind a given program is recorded in our pharmacy register, and the programs themselves sit on the compounded tirzepatide board.
Frequently Asked Questions
References
- 1.Eli Lilly and Company ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information (boxed warning; sections 1, 5.2, 5.3, 5.4, 5.5, 5.8, 6.1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 2.Eli Lilly and Company MOUNJARO (tirzepatide) injection, for subcutaneous use — prescribing information (sections 1, 5, 14.6) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2d7da5d-ad07-4228-955f-cf7e355c8cc0
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387(3):205-216. 2022. PMID: 35658024.
- 4.Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 2025;392(10):958-971. 2025. PMID: 39536238.
- 5.Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. 2024. PMID: 38078870.
- 6.Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med 2025;393(24):2409-2420. 2025. PMID: 41406444.
- 7.Nissen SE, Wolski K, D'Alessio D, et al. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol 2026;11(6):544-552. 2026. PMID: 41903177.
- 8.Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025. 2025. PMID: 39996356.
- 9.U.S. Food and Drug Administration Drugs@FDA: MOUNJARO (tirzepatide), NDA 215866 — original approval May 13, 2022 FDA Drugs@FDA database. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866
- 10.U.S. Food and Drug Administration Drugs@FDA: ZEPBOUND (tirzepatide), NDA 217806 — original approval November 8, 2023 FDA Drugs@FDA database. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
- 11.Eli Lilly and Company A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO), NCT05556512 ClinicalTrials.gov, U.S. National Library of Medicine. 2026. https://clinicaltrials.gov/study/NCT05556512
Compare the sellers
Related research
Is Compounded Tirzepatide Safe? What FDA Has Actually Reported
FDA has never reviewed compounded tirzepatide for safety, effectiveness or quality. That is a fact about regulatory review, not a finding of harm. This covers what the agency has reported, what separates a 503A pharmacy from a 503B facility, and what nobody can tell you.
11 min read
GLP-1 Eye Risks: Diabetic Retinopathy and NAION Are Not the Same Thing
Two distinct eye questions get merged into one headline. Diabetic retinopathy complications are on the semaglutide label and trace to blood sugar falling fast; NAION is a separate optic-nerve signal that Europe's drug-safety committee recommended adding to product information in June 2025, and US labeling still does not mention.
12 min read
Compounded Semaglutide: Is a Prescription Required?
Yes, but 503A and 503B do not carry the same requirement, and the gap between them is where the no-prescription pitches live. What each route actually asks for.
5 min read
Which GLP-1s Can Be Compounded? The FDA Shortage and Bulks-List Rules
Both federal routes for compounding semaglutide and tirzepatide depended on FDA shortage status. Both shortages are closed, and FDA has proposed shutting the remaining route.
7 min read
How Long Do Semaglutide and Tirzepatide Side Effects Last?
What predicts side effects is where you are on the ladder, not how many weeks you have been taking it. Both labels place the nausea and diarrhea during escalation, and how long any single dose keeps working comes down to half-life: roughly seven days for semaglutide, roughly five for tirzepatide.
11 min read
How to Verify an Online GLP-1 Pharmacy: Six Public Checks
Every check starts with the name of the dispensing pharmacy: the state board license database, FDA's 503B register and FDA's warning letters are all free, public, and take about ten minutes.
10 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HealthRX
From $214/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →Collective
From $69/mo + membership
Get started →